Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials

Visit https://www.peervoice.com/MGY860 to view the entire programme with slides. After completing “Marianna Fontana, MD, PhD / Julian Gillmore, MD, PhD, FRCP, FRCPath - Identifying Outcomes That Matter in ATTR-CM: Critical Considerations in the Interpretation of Contemporary Clinical Trials”, participants will be able to: Compare the study designs and endpoints of pivotal phase 3 clinical trials in transthyretin amyloid cardiomyopathy (ATTR-CM); Identify the differences in baseline characteristics of study populations in key phase 3 trials in ATTR-CM and their impact on study outcomes; and Evaluate the clinical relevance and practical applicability of available study outcomes from pivotal trials in ATTR-CM.